Analysis item
cancer, ocular toxicity
CANCER, ADVERSE EVENT
We retrospectively reviewed patients’ medical records for details on sex, age (at enrolment), cancer type, details of the investigational drug (dose, date of initiation, and date of last dose), and ocular toxicity (symptoms, grade, association with the investigational drug, onset date, and recovery or last follow-up date). Symptoms and grades of ocular toxicity were assessed according to the Common Terminology Criteria for Adverse Events (version 5.0) [This study was approved by the Institutional Review Board of NCCH (NCCH 2014–148), which waived the requirement for informed consent. The study was conducted according to the principles of the Declaration of Helsinki.